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3Public Health Interventions have Varying Effects
on Longevity, Morbidity, and Years of Healthy Life 
1.0 Introduction
The performance of public health interventions is not always easy to understand.
Here, we examine some features of interventions by considering the public as a system 
consisting of three health states, healthy, sick, and dead, as shown in Figure 1.  The status 
of a system at some point in time is completely defined by its initial conditions (the 
number of persons in the healthy and sick states at baseline) and the probabilities of 
transition among the states (shown in Figure 1 for age 65 and explained in more detail 
later).  Public health interventions may attempt to improve health by changing the initial 
conditions or by modifying the transition probabilities.   
One approach is to improve initial conditions by moving all persons in the sick 
state to the healthy state at baseline (referred to later as the Cure All intervention).   
Another approach is to decrease the probability that healthy persons become sick, 
through health promotion or disease prevention programs (HP/DP).  Improved treatment 
can increase the probability that sick persons recover (Treatment).  Interventions such as 
improved ICU care may lower the probability that sick persons will die (ICU).  Finally, 
interventions to improve traffic, gun, or workplace safety could reduce the probability of 
death for healthy persons (Safety).  It is also possible to combine interventions, such as 
HP/DP + Cure All, or HP/DP + ICU.  Such interventions are likely to have different 
effects on longevity or years of life (YOL), years of healthy life (YHL), morbidity or 
years of sick life (YSL), and on medical expenditures.  These interventions are described 
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4in more detail below.  The names of the intervention types do not refer to real 
interventions, but were used to help readers remember the intervention’s primary feature.   
[Figure 1 about here] 
Multi-state lifetable methods have been used to estimate the consequences of 
modifying the transition probabilities, decreasing the prevalence of certain diseases or 
causes of death, or of meeting the year 2000 objectives, on mortality and morbidity  1 2 3
4 5 6 7 8 9 10 11    and medical care expenditures. 12  Morbidity has usually been defined in 
terms of (instrumental) activities of daily living ((I)ADLs).  Current literature usually 
involves older adults (65 or older), and does not deal specifically with the type of 
interventions that might achieve such changes.  Here, we examine the effect of different 
interventions on YOL, YHL, YSL, and medical expenditures.  We defined Healthy as 
being in excellent, very good, or good health and Sick as being in fair or poor health, and 
used transition probabilities estimated elsewhere from three large datasets. 13   We 
expected the effectiveness of an intervention to depend on the intervention target, the 
type of intervention, and the initial health and age of the target population.  We 
intentionally used a very simple model so that the findings could be understood 
intuitively. 
2.0  Methods
2.1 Health states and transition probabilities 
For readers unfamiliar with multi-state life table calculations, we present the 
following example.  Consider a cohort with 80,000 healthy and 20,000 sick persons at 
age 65 (similar the U.S. distribution).  Figure 1 shows the estimated transition 
probabilities at age 65, which can be used to estimate the number who will be in each 
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5health state one year later, at age 66.  Of the 80,000 healthy persons, the probabilities 
indicate that .09*80,000=7200 persons are expected to be sick one year later, 800 will be 
dead, and 72,000 will still be healthy.  Of the 20,000 sick persons, 12,200 will remain 
sick, 6800 will become healthy, and 1000 will die.  Thus, at age 66, there would be 
72,000+6800=78,800 healthy persons, 19,400 sick persons, and 1800 dead persons.  The 
process can be repeated each year, using age-specific transition probabilities, until all 
subjects have died.  At that point the total number of person-years spent in the healthy 
and sick states can be calculated, to yield estimates of the years of healthy life (YHL), 
years of sick life (YSL), and years of life (YOL).  We considered both a Birth cohort
(beginning at age 0) and a Retiree cohort (beginning at age 65), with initial conditions 
taken from national data.  Multi-state life table software implemented in Stata was used. 
14
Figure 2 shows transition probabilities from age 0 to 100, estimated as explained 
below and listed in more detail in an on-line technical report.15  Figure 3 shows the 
number of persons in a Birth cohort who are predicted to be healthy or sick at each age.  
(The number who are dead is not shown).  The solid lines represent a Birth cohort of 
100,000 persons in which everyone was healthy at birth, and the dashed lines a cohort in 
which everyone was in the sick state at birth.  Note that even in the “start sick” cohort, 
most persons are healthy after a few years because P(H|S) is high at the younger ages (see 
Figure 2). Importantly, until about age 80 the number of sick persons is small relative to 
the number who are healthy. The number healthy and sick quickly reach an equilibrium 
ratio determined by the transition probabilities, and the initial health state becomes fairly 
unimportant.13  The areas under the two “# Healthy” curves are the expected years of 
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6healthy life (YHL), and differ for the two cohorts primarily because of the differences 
near age zero.  The area under the “# Sick” curves is years of sick life (YSL) or 
morbidity.
 [Figure 2 and Figure 3 about here] 
We also looked briefly at a 5-state model that considered the health state the year 
before baseline.  The Sick state was divided into Newly Sick (Sick now but Healthy 1 
year earlier), Still Sick (Sick at both times), and the Healthy state was divided into Newly 
Healthy and Still Healthy.  As this model was more complex and required estimating 
more transition probabilities from less available data, findings are mentioned only briefly 
in the discussion section.
2.2 Interventions 
Modifying the initial conditions and/or the transition probabilities permitted us to 
examine the performance of different interventions, listed in Table 1.  The “Status Quo” 
intervention made no change and is the basis for comparison.  “Cure All” moved all of 
the sick persons to the healthy category at baseline only.  We also defined four 
hypothetical interventions, each of which affected one and only one of the transition 
probabilities in Figure 1. We calculated the effect of “improving” each of the 
transition probabilities by 100*Į%.  This improvement is defined as either multiplying 
P(H|S) by 1+ Į, or multiplying P(S|H), P(D|H), or P(D|S) by 1-Į.  The change in YHL 
and YSL caused by this intervention is a complicated function of powers of Į.  If Į is 
small, the higher order terms can be ignored, and changes in the outcomes are essentially 
quadratic in Į.  Preliminary analyses shows that for Į < about .3, the relationship was 
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7approximately linear, with a zero intercept, except for Cure All and Cure All + HP/DP.  
This feature will be discussed later on.  Finally, we evaluated the two combined 
interventions shown in Table 1. The transition probabilities that are modified are shown 
in Figure 1. We compared each intervention to the “Status Quo” intervention.   
2.3 Data
Age-specific transition probabilities have been developed for self-rated health (is 
your health excellent/very good/ good/ fair/ poor), referred to as EVGGFP, based on all 
three large datasets.13   The Cardiovascular Health Study (CHS) is a population-based 
longitudinal study of 5,888 adults aged 65 and older at baseline, described in detail 
elsewhere.16 17   Subjects were recruited from a random sample of the Medicare eligibility 
lists in four U.S. counties.  EVGGFP was obtained every 6 months for 14 years (to date), 
beginning in 1990.   These 5,888 subjects contributed about 150,000 transition pairs (two 
EVGGFP values for the same person measured one year apart).  
 Transition information was also taken from two large national surveys,  the 
Medicare Current Beneficiary Study (MCBS) 18  and the Medical Expenditures Panel 
Survey (MEPS).19  In MCBS, persons were followed 2 to 6 years, and about 41,000
persons contributed about 98,000 transition pairs from age 65 to 100.   In the MEPS 
dataset, approximately 93,000 persons contributed about  224,000 transition pairs for 
ages 0 to 64, and  29,000 transition pairs for ages 65-85.
National estimates of the % of older adults who were in excellent, very good, or 
good health (Healthy) or in fair or poor health (Sick) at ages 0 and 65 came from the 
National Health Interview Survey. 20  Data on medical expenditures by age and health 
state were calculated from MEPS data collected in 2002, using the MEPSNET software.  
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2.4 The Value of an additional YHL or YSL 
 To choose the “best” intervention, we must define the incremental value to 
society and the cost of implementing the intervention; we will then select the intervention 
that provides the most incremental value per increase in cost.  Let the value to society be 
proportional to YHL + b*YSL, where b is a number less than or equal to 1.  If b=1, then 
society is indifferent to the healthy and sick states, and would seek to maximize life 
expectancy, only incidentally increasing YHL.  If b = 0, then society is indifferent to the 
sick and dead states, and the intervention that maximizes years of healthy life would 
provide the most value.  We examined a range of values between 0 and 1, and also b= -
0.25, to consider the situation when the sick state is “a state worse than death”.22   For 
each pair of interventions we calculated the ratio of implementation costs at which one 
would be more cost-effective than the other, as explained below. 
2.5 Analysis 
We estimated the effect of a 100 Į% improvement in a transition probability,  
where Į = +.10. For  HP/DP+Cure All, we moved sick persons to the healthy state at 
baseline and also improved P(S|H) by Į.  For HP/DP+ICU, we improved both P(S|H) and 
P(D|S) by Į.  We estimated the total YOL, YHL, and YSL for a cohort of size 100,000 at 
baseline, using the multi-state life table software.  This was done for two cohorts:  a Birth 
cohort (from age 0 to 100) and a Retiree cohort (from age 65 to 100).  We also estimated 
average lifetime medical expenditures as the number of persons projected to be in each 
health state at each age multiplied by the average medical expenditure for that state and 
age, summed and divided by 100,000.    
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93.0 Findings 
3.1 Table 1 shows the estimated number of years of healthy life, years of sick life, 
and years of life for each intervention, in the two cohorts, and depending on whether the 
cohort was healthy or sick at baseline.  For example, the first line shows that under the 
Status Quo, persons in the Birth cohort who are healthy at baseline average  67.87 
healthy years and 9.51 sick years, adding to 77.38 years of life (life expectancy).  Values 
for persons sick at baseline are also shown.   The final three columns are estimates when 
the percent healthy and sick at baseline agree with national estimates.  The Birth cohort 
was set to 98% initially healthy and 2% sick at baseline; the Retiree cohort was set to 
80% healthy and 20% sick at baseline.  That is, the population YHL estimate for the Birth 
cohort would be .98*the number of YHL in the initially healthy cohort + .02*the number 
of YHL in the initially sick cohort.  The second line of Table 1 shows results for the Cure 
All intervention.  Note that the outcomes for the initially healthy cohort are identical to 
the Status Quo outcomes (since Cure All did not affect the Healthy state) and that the 
outcomes for the Sick cohort are identical to those for the initially Healthy cohort, since 
all sick persons were moved to the Healthy state at baseline.  Results are given for the 
other interventions, and for the Birth cohort. 
[Table 1 about here] 
3.2.0 Incremental change in YHL, YSL, and YOL due to an intervention
Columns 2, 3, and 4 of Table 2 are the same as the last three columns of Table 1, 
but the value for the Status Quo is subtracted from each line.  For example, dYHL 
(change in YHL) is 0 for the Status Quo intervention, by definition. The Cure All 
intervention achieved 0.067 additional years of healthy life in the Birth cohort, which is 
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the entry in the second row of Table 2.  It also decreased YSL (years of sick life, or 
morbidity) by 0.009 years and increased survival by .059 years.  The effects of the Cure 
All intervention were larger in the Retiree cohort.  Column 5 shows the estimated 
difference in future medical expenditures attributable to the intervention. All 
interventions improved YHL and YOL (the numbers in the dYHL and dYOL columns 
are positive).  The Safety and ICU interventions increased morbidity (dYSL) and medical 
expenditures (d$), while the others interventions decreased them.   HP/DP + ICU 
decreased YSL but increased medical expenditures nonetheless.   
The values in columns 2-5 of Table 2 are the amount of improvement in outcomes  
if Į = .10.  However, the amount of improvement is approximately linear in Į through the 
origin for Į < .3 (except for Cure All and Cure All+ HP/DP). Table 2 thus also provides 
the amount of change that would occur for Į=.05 (half the amount in Table 2) or Į=.2
(twice the amount of Table 2).  The linearity also held for negative values of Į; that is, if 
we made the probabilities 10% worse instead of 10% better, the change in  outcomes 
would be the amount shown in the tables multiplied by -1.   Changing the sign is not 
appropriate for Cure All.  The effect of curing only, say, half of the persons at baseline is 
equal to half of the values in Table 2 for Cure All.  The HP + Cure All also cannot be 
modified in this way, because the relationship with Į is linear but not through the origin 
(the intervention does not reduce to the Status Quo when Į=0).
[Table 2 about here] 
3.3 Cost-Effectiveness of an Intervention 
It is reasonable to assume that the incremental value of an intervention to society 
is proportional to dYHL + b * dYSL, where b is the value of an additional YSL divided 
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by the value of an additional YHL.  We examined values of b from -0.25 to 1.0.  Column 
6 of Table 2 shows the incremental value of each intervention for Į = .10 and b = 0.5.  In 
the Birth cohort the two combined interventions provided the most value, followed by 
HP/DP.  Results are similar for the Retiree cohort except that Cure All is the best simple 
intervention.  Results for other values of b may be inferred from column 3.  Interventions 
that decrease YSL produce more value if b (the relative worth of a YSL) is low, while 
interventions that increase YSL have more value if b is high.  In the Birth cohort, HP/DP 
produced the most value of all the single interventions if b <0.7975, and ICU was most 
valuable for higher values of b.  The corresponding threshold in the Birth cohort was 
0.6076.  Thus, the “best” intervention depends on the relative value to society of an 
additional YSL.  The calculations for other values of b are in Appendix Table B. 
Although Column 6 allows us to compare the value of interventions that were 
improved by a factor of Į =.10, the Cure All intervention was not standardized in this 
way and so cannot be compared to the others.  To improve comparability, column 7 
shows the value of Į that would be needed for each intervention to produce as much 
value as the Cure All intervention.  For example, in column 6 of Table 2 for the Retirees, 
the value of Cure All is .4180 and the value of HP/DP is .3590.  To increase the value of 
HP/DP to the Cure All level, we must multiply its value by .4180/.3590 = 1.164.  
Because incremental value is a linear function of Į, through the origin, the Į that will 
achieve this change is 1.164 * .10 = .1164, which is tabled in Column 7.   (The required Į
is 0 for HP/DP + Cure All because it can achieve as much value as Cure All alone 
without using HP/DP).  In the Birth cohort, Cure All is equivalent to Į of about 0.01, 
while in the Retiree cohort it is equivalent to Į between 0.1 and 0.2.  Lower values are 
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preferred in Column 7, since they indicate that only a small dose of the row intervention 
is needed to be equivalent to the Cure All intervention.  In both cohorts, HP/DP is the 
best single intervention and HP/DP + ICU is the best over-all intervention.
Assessment of cost-effectiveness requires specifying the cost of implementing 
and maintaining an intervention that improves a transition probability by 100Į% (or the 
cost of curing all sick persons at baseline).  Here, we assume that the cost of the 
intervention is proportional to the amount of change required in the transition 
probabilities, Į.  For instance, the cost to achieve an improvement of Įh using HP/DP is 
assumed to be Ch* Įh, and the cost of achieving an improvement of Įi using ICU is Ci* Įi.
From column 7 of Table 2, the cost to achieve a value of .0625 using HP/DP is Ch * 
.0084 and the cost to achieve a value of .0625 using ICU is Ci * .0135.  These two costs 
are the same if Ch = Ci * .0135/.0084 = Ci * 1.616.  HP/DP is cost-effective relative to 
ICU if Ch < 1.616 * Ci.  Table 3 shows the cost ratio that is required for the column 
intervention to be more cost-effective than the row intervention.  As above, if the cost of 
HP/DP is 1.616 times the cost of ICU, or less, then HP/DP is more cost-effective (column 
2, row 6).  In the Retiree cohort, Cure All is cost effective compared to HP/DP if Cure 
All costs less than 0.116 times the cost of HP/DP (column 1, row 8).  Although the costs 
of a particular implementation are unknown in this exercise, these relative numbers may 
be useful.  It is clear, for instance, that in the Birth cohort, Cure All would not be chosen 
unless it cost less than 1% as much as another intervention. 
[Table 3 about here].
4.0 Summary and Discussion 
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The eight interventions all improved YHL and YOL, but some of them increased 
morbidity and medical expenditures.  The “best” intervention depended on society’s 
evaluation of a YSL relative to a YHL, with the ICU intervention best if YSL is highly 
valued and HP/DP best if  an additional YSL is less highly valued.  In the following we 
discuss how the interventions perform, costs of implementation, theories about the 
changes in morbidity, the contribution of this work to the literature, limitations and 
conclusions.
4.1     How do the interventions perform? 
Some characteristics of the performance may be discerned from the transition 
probabilities in Figure 2.  Interventions that improve the transition probabilities are likely 
to have little effect at the youngest ages, because the probabilities are already favorable.
Figure 3 shows that even if everyone is sick at baseline, the number of persons in the sick 
state at any time is small after a few years, because the probability of recovery and the 
probability of remaining healthy are high.  The Cure All, Treatment, and ICU 
interventions are unlikely to have much population effect at younger ages, because there 
are few sick persons to be intervened upon.  All of the interventions should be more 
effective in the Retiree cohort, because the transition probabilities are more amenable to 
improvement and the number of sick persons is higher.   
The Cure All intervention is equivalent to replacing the dashed lines in Figure 3 with 
the solid lines (making all the sick persons healthy at baseline).    The area between the 
top solid and dashed curves in Figure 3 (multiplied by the proportion of persons who are 
initially sick) is the YHL associated with the Cure All intervention.  Clearly, the effect of 
Cure All on YHL is short-term, and is small if there are few sick persons to be cured at 
Hosted by The Berkeley Electronic Press
14
baseline. That is why Cure All performs better in the Retiree cohort. The gain in YHL 
and YOL is due to the extra time spent in the healthy state while the population is 
reaching equilibrium.  The effect of curing only half of the persons who were sick at 
baseline can be obtained by dividing the values in Table 2 by 2. 
The Treatment, HP/DP, and Cure All interventions work by keeping more persons 
in the Healthy state, thus directly improving YHL and YSL.  They have an indirect effect 
on YOL because persons in the Healthy state have a lower mortality rate.  The ICU 
intervention keep sick persons from dying, thus directly increasing YOL and YSL, and 
indirectly increasing YHL because persons have a longer time in which to recover to the 
Healthy state.  The Safety intervention directly increases YOL and YHL, but also 
somewhat surprisingly increases YSL, presumably because persons saved have a longer 
live long enough to accumulate YSL instead of dying young.  The net effect of these 
considerations is that the former three interventions decrease medical expenditures, while 
the latter two increase medical expenditures.   
The combined interventions performed differently.  The value of HP/DP + Cure 
All (.8110 in the Birth cohort) was slightly better than the sum of the values of  HP/DP 
and Cure All alone (.7480+.0625 = .8105).  This apparent synergy may occur because the 
two interventions act on different parts of the age distribution, with Cure All having a 
short-term effect of increasing the number of healthy persons for the HP/DP intervention 
to affect. The HP/DP + ICU intervention provided slightly less value than the sum of its 
components, possibly because the HP/DP intervention kept persons from getting sick, 
leaving the ICU intervention with fewer persons on whom to intervene. It is also 
interesting that HP/DP+ICU increased medical expenditures even though it decreased 
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YSL.  Presumably this is because it made relatively large changes in YOL but relatively 
small decreases in YSL. 
4.2 Costs of interventions
 The HP/DP intervention might have low costs per person, but as it is applied to all 
healthy persons it might be an expensive intervention. ICU may have high per-person 
costs, but the number of sick persons to whom it would be applied is relatively low (as 
seen in Figure 3).   It might be expensive to cure everyone at baseline, particularly if 
discounted costs are calculated, since the Cure All intervention will need to spend money 
up front, while other interventions will accrue costs (and benefits) over time.  On the 
other hand, Cure All accrues most of its benefit early on, and discounting of the benefit 
(which is usually done when costs are discounted) would tend to favor Cure All for that 
reason.  Further research is needed into the costs of such interventions.  It would then be 
possible to calculate whether the savings in future medical expenditures might offset 
some of the costs of the interventions. 
4.3  Morbidity hypotheses 
These results shed some light on various hypotheses about morbidity and aging.  
The compression of morbidity hypothesis was first proposed by Fries, who suggested that 
adult life expectancy is approaching its biological limit.  If the incidence of incapacitating 
disease can be postponed to later ages, morbidity will then be compressed into a shorter 
period of life.23    A related question is whether it is possible to increase YOL without 
also increasing YSL. We found that Cure All, HP/DP and Treatment may compress 
morbidity, while ICU may expand it. Another morbidity hypothesis is Manton’s 
“dynamic equilibrium”, which suggests that improvements in medical care will result in 
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more sick persons, but that they will not be as sick on average as those who are currently 
sick.24 Empirical evidence supports this hypothesis.25 26  Separate analyses (not shown) 
suggested that the Safety intervention was consistent with the dynamic equilibrium 
hypothesis.
In the terms of our 5-state model, the dynamic equilibrium hypothesis suggests 
that the mix of “Still Sick” and “Newly Sick” within the Sick state might change due to 
an intervention.  We found that Cure All made essentially no change in YSL (as 
compared to the 3-state model) but decreased the % of sick years spent in the sickest state 
(Still Sick).  The ICU intervention increased YSL and increased the % of sick years in the 
sickest state.  The Safety intervention increased YSL and decreased the % of years in the 
sickest state.  Cure All thus led to compression of morbidity in the sickest state only, ICU 
led to expansion of morbidity, and Safety led to dynamic equilibrium. We did not 
evaluate the HP/DP or Treatment interventions for the 5-state model because it was 
unclear how to modify the larger number of probabilities to correspond to the 3-state 
model.  It seems likely that both interventions would result in compression of morbidity.  
Different types of interventions would thus support different theoretical morbidity 
models.  Since the empirical data has supported the dynamic equilibrium hypothesis, this 
may suggest that interventions of the “Safety” type have occurred recently.  Additional 
research is needed in this area.  Appendix A contain information on the 5-state model. 
4.4 Other possible comparisons   
We have presented only a few interventions and combinations of interventions, 
but many other comparisons are possible from the information presented here.  A “Cure 
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half” intervention would have half the value of the Cure All intervention.  The effect of 
combining Cure All with any of the other interventions is available from Table 1, using 
only the initially healthy cohort (the first 3 columns in Table 1).  To assess the effects of 
a pandemic that sickened all of the healthy newborns, Figure 3 and Table 1 show that the 
Birth cohort would return to its equilibrium ratio of healthy to sick by about age 5.    The 
effect of a different health problem that changed the transition probabilities in a negative 
way can be obtained by changing the signs in Table 2.  It is easy to calculate the value to 
society for different values of b.  Thus, these results are applicable to a variety of other 
situations. 
4.5  Limitations 
In this section we discuss limitations due to the nature of the interventions, health 
states, the transition probabilities and medical expenditures. 
4.5.1  Interventions 
The interventions considered are of course unrealistic.  The names were assigned 
simply for mnemonic purposes.  There are probably few interventions that would affect 
only a single transition probability, or which could be applied at the same “dose” for 
persons of all ages.  It is likely that a variety of age-appropriate interventions are 
required, at varying strengths, to make an improvement of Į.    Only small values of Į
were considered, but this seems reason as it may be difficult to achieve larger changes at 
the population level.
4.5.2  Health States 
To simplify the problem, we considered a system with only three health states.  
Dividing the Sick state into Fair versus Poor,27 or chronic versus acute illness, might have 
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provided additional insights, although relatively few persons were sick at any time. 
Findings from the 5-state model are mentioned below.  The states were defined based on 
EVGGFP, but could have been based on the more common activities of daily living 
measure.  If so, we would have estimated active life expectancy rather than years of 
healthy life.  The resulting three-state system would have different transition 
probabilities.  The conclusions about the relative performance of the different 
intervention types would probably have been similar, but this must be verified elsewhere.   
4.5.3  Transition Probabilities 
 The transition probabilities were estimated from three general populations and are 
age-specific, so they should represent the Status Quo adequately.  It is possible, however, 
that the interventions will change the average transition probabilities for a state, in that 
they may change the health distribution within each health state. We used small values of 
Į to minimize these problems. In addition, we ignored gender, in the interest of 
simplicity.  Gender-specific transition probabilities would have resulted in different 
values but not, we believe, in different findings about the relative behavior of the 
interventions.  As in all such calculations, the transition probabilities at later ages may not 
be appropriate for those in the 2005 Birth cohort, and these estimates cannot be exact. 
We briefly considered the 5-state model where the “sick” state was divided into 
two sub-states,  “Newly Sick” and “Still Sick”, with different transition probabilities.  We 
examined the effect of the Cure All,  Safety, and ICU interventions in the Retiree Cohort.
Cure All (moving the sick to Newly Healthy at baseline) decreased the % of sick years 
spent in the Still Sick state from 63% to 60%. ICU increased the % from 63% to 68% 
(using alpha = -.43, which would improve YHL from 13.12 to 14.0 years in the Retiree 
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cohort).  Safety decreased the % from 63% to 62% (using alpha = -.33, which improved 
YHL by the same amount). An intervention can thus change the mix of cases within the 
sick state, and could affect the validity of the probabilities used in the 3-state model for 
that intervention.  However, the shift was not large and probably had little practical 
effect.  We limited the investigation to smaller values of alpha, where the effect should be 
even smaller. 
4.5.4  Medical Expenditures 
Medical expenditures were estimated from a single year of MEPS data, and were
extrapolated for ages 85 to 100.  As relatively few persons achieve that age, the effect of 
this extrapolation is probably small, but the expenditure estimates should be considered 
only approximate.   Some of the interventions resulted in decreased lifetime medical 
expenditures for the cohort.  However, most of these savings (or additional expenditures) 
would disappear under the traditional 3% discounting for costs accrued over time. Small 
changes in expenditures in Table 2 are well within the range of error. 
4.6   Conclusion 
 Although a good deal of research has considered the mortality and disability 
patterns of cohorts,  we believe that our paper is the first to calculate years of healthy life 
from multi-state life table probabilities for this purpose, and the first to calculate 
transitions for the entire age range.  This may be the first time that the effects of specific 
types of interventions have been compared, and some insights have been gained as to the 
way they operate. 
Hosted by The Berkeley Electronic Press
20
The small number of sick persons at any age is a tribute to today’s public health 
strategies, and perhaps the situation can be improved further by appropriate public health 
interventions, especially at older ages.  The apparent success of the Cure All intervention 
in the Retiree cohort suggests that comprehensive health screening and treatment for new 
Medicare enrollees might improve health and even lower future expenditures.  Favorable 
results for Cure All + HP/DP interventions suggest such an intervention could have even 
better effects.
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Table 1 
Outcomes*  by Baseline State by Cohort 
Healthy at Baseline Sick at Baseline 
US Distribution at 
Baseline ** 
          
Intervention              YHL YSL YOL YHL YSL YOL YHL YSL YOL 
Birth Cohort 
Status Quo 67.87 9.51 77.38 64.52 9.94 74.46 67.80 9.52 77.33
Cure All 67.87 9.51 77.38 67.87 9.51 77.38 67.87 9.51 77.38
HP/DP 68.97 8.81 77.78 65.57 9.27 74.84 68.90 8.82 77.72
Treatment 68.72 8.96 77.69 65.55 9.31 74.86 68.66 8.97 77.63
ICU 68.20 9.77 77.97 65.09 10.23 75.32 68.14 9.78 77.92
Safety 68.24 9.63 77.87 64.87 10.06 74.92 68.17 9.64 77.81
HP/DP+Cure All 68.97 8.81 77.78 68.97 8.81 77.78 68.97 8.81 77.78
HP/DP+ICU 69.29 9.05 78.34 66.13 9.54 75.67 69.22 9.06 78.28
 Retiree Cohort 
Status Quo 13.12 4.28 17.40 10.44 5.45 15.90 12.58 4.52 17.10
Cure All 13.12 4.28 17.40 13.12 4.28 17.40 13.12 4.28 17.40
HP/DP 13.62 4.02 17.64 10.84 5.24 16.09 13.07 4.26 17.33
Treatment 13.43 4.12 17.55 10.94 5.20 16.14 12.93 4.34 17.27
ICU 13.30 4.50 17.79 10.71 5.71 16.43 12.78 4.74 17.52
Safety 13.36 4.38 17.74 10.64 5.53 16.17 12.82 4.61 17.43
HP/DP+Cure All 13.62 4.02 17.64 13.62 4.02 17.64 13.62 4.02 17.64
HP/DP+ICU 13.80 4.22 18.01 11.12 5.49 16.60 13.26 4.47 17.73
* Years of healthy life, years of sick life, andYears of life due to a 10% improvement (Į
= .10) using the listed intervention.  For Cure All, the intervention cures everone at 
baseline (Į is irrelevant).  For HP/DP+Cure All, everyone is cured at baseline and Į  =
.10 for the HP/DP intervention).
** U.S. distribution at baseline is assumed to be   98% Healthy and 2% Sick for the Birth 
cohort; it is 80% Healthy and 20% Sick for the Retiree cohort.  
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Table 2 
Improvements in Outcomes for the Interventions  
(10% improvement) 
1 2 3 4 5 6 7 
Intervention dYHL dYSL dYOL d$ 
Value
(b=5) Required Į
       
  Birth cohort     
       
Status Quo 0 0 0 0 0  
Cure All 0.067 -0.009 0.059 -122 0.0625  
HP/DP 1.098 -0.7 0.398 -1283 0.7480 0.0084 
Treatment  0.857 -0.555 0.303 -1070 0.5795 0.0108 
ICU 0.334 0.258 0.592 4943 0.4630 0.0135 
Safety 0.368 0.119 0.486 3404 0.4275 0.0146 
HP/DP + Cure All 1.166 -0.71 0.456 -1407 0.8110 0 
HP/DP + ICU  1.42 -0.464 0.956 3352 1.1880 0.0053 
      
 Retiree cohort     
      
Status Quo 0 0 0 0 0.0000  
Cure All 0.535 -0.234 0.301 -2 0.4180  
HP/DP 0.485 -0.252 0.233 -8 0.3590 0.1164 
Treatment  0.346 -0.178 0.167 6 0.2570 0.1626 
ICU 0.197 0.222 0.42 4079 0.3080 0.1357 
Safety 0.237 0.092 0.329 2676 0.2830 0.1477 
HP/DP + Cure All 1.041 -0.497 0.544 -8 0.7925 0 
HP/DP + ICU  0.677 -0.046 0.632 3846 0.6540 0.0639 
Columns: 
1:  Name of intervention 
2:  dYHL=YHL for the row intervention minus YOL for the Status Quo 
3:  dYOL=YOL for the row intervention minus YHL for the Status Quo 
4:  dYSL=YSL for the row intervention  minus YSL for the Status Quo 
5:  d$ = Total medical expenditures for the row intervention minus expenditures for the 
Status Quo. 
6:  Value to society of the row intervention minus value of the Status Quo, calculated as 
dYHL + .5*dYSL. 
7:   Level of Į required for the row intervention to provide as much incremental value as 
the Cure All intervention, calculated as the column 6 entry for Cure All divided by the 
column 6 entry for the row intervention, multiplied by 0.10. 
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Table 3 
Cost Ratio* required for Column Intervention  
To be more Cost-effective than Row Intervention 
(b = 0.5) 
       
 Cure All HP/DP Treat Safety ICU H+I 
       
Cure All 1.000 119.680 92.720 68.400 74.080 190.080
HP/DP 0.008 1.000 0.775 0.572 0.619 1.588
Treat 0.011 1.291 1.000 0.738 0.799 2.050
Safety 0.015 1.750 1.356 1.000 1.083 2.779
ICU 0.013 1.616 1.252 0.923 1.000 2.566
H+I 0.005 0.630 0.488 0.360 0.390 1.000
   
 Cure All HP/DP Treat Safety ICU H+I 
      
Cure All 1.000 8.589 6.148 6.770 7.368 15.646
HP/DP 0.116 1.000 0.716 0.788 0.858 1.822
Treat 0.163 1.397 1.000 1.101 1.198 2.545
Safety 0.148 1.269 0.908 1.000 1.088 2.311
ICU 0.136 1.166 0.834 0.919 1.000 2.123
H+I 0.064 0.549 0.393 0.433 0.471 1.000
       
* If the cost of the column intervention is less than the tabled amount times the cost of the 
row intervention, then the column intervention is more cost-effective.  The tabled value is 
calculated as the “required alpha” from Table 2 for the row variable divided by the 
required alpha for the column variable. 
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Figure 1 
Transitions Among Three Health States for Age 65
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Figure 2 
One-year Transition Probabilities [check this] 
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Figure 3 
Estimated # of healthy, sick and dead persons in Birth cohort 
(All Healthy or All Sick at Birth) 
Number in Each Health State
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Appendix Table A 
Summary of results dealing with dynamic equilibrium and shift into 
sicker/healthier states because of the intervention.
The tables show results for the 5-state model.  HH refers to the “still healthy” state, 
SH is “newly healthy”, HS is “newly sick” and ss is “still sick”.  The next yhl is 
HH+SH, ysl is HS+SS.  YOL is YHL+YSL.  HH/YHL through YSL/YOL are ratios. 
The first two rows give the number of years in the state under the status quo and 
under the intervention.  Line 3 shows the difference between the two and line 4 shows 
the ratio.  Below, there is similar information for the 3-state model, taken from Table 
2.  The shaded cells are referred to in the text. 
summary table for Cure All, 69044 start HH, 30956 start SH  
hh sh hs ss yhl ysl yol hh/yhl ss/ysl ss/yol ysl/yol
5 state 
Status
Quo 10.331 1.286 1.652 2.758 11.617 4.410 16.027 0.889 0.625 0.172 0.275
Cure all 10.319 1.323 1.761 2.659 11.642 4.419 16.061 0.886 0.602 0.166 0.275
diff -0.012 0.037 0.109 
-
0.100 0.025 0.009 0.034 -0.003
-
0.024
-
0.007 0.000
ratio 0.999 1.029 1.066 0.964 1.002 1.002 1.002     
           
3 state 
table 2 Status 
Quo    12.580 4.520 17.100    0.264
cure all     13.120 4.280 17.400    0.246
diff2     0.540
-
0.240 0.300    -0.018
ratio     1.043 0.947 1.018     
             
  9-16-2005, cure sick by moving them to SH, hh=69044, sh = 30956   
             
summary table for Cure All, 100K start out healthy healthy  
hh sh hs ss yhl ysl yol hh/yhl ss/ysl ss/yol ysl/yol
Status
Quo 10.331 1.286 1.652 2.758 11.617 4.410 16.027 0.889 0.625 0.172 0.275
Cure
All 11.739 1.097 1.665 2.251 12.836 3.916 16.751 0.915 0.575 0.134 0.234
diff 1.408
-
0.189 0.013
-
0.508 1.219
-
0.495 0.724 0.025
-
0.051
-
0.038 -0.041
ratio 1.136 0.853 1.008 0.816 1.105 0.888 1.045     
           
table 2
Status
Quo    12.580 4.520 17.100    0.264
cure all     13.120 4.280 17.400    0.246
diff2     0.540
-
0.240 0.300    -0.018
ratio     1.043 0.947 1.018     
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summary table for equal YHL Safety intervention   
hh sh hs ss yhl ysl yol hh/yhl ss/ysl ss/yol ysl/yol
5
state
Status
Quo 10.331 1.286 1.652 2.758 11.617 4.410 16.027 0.889 0.625 0.172 0.275
safety 
10% 11.169 1.358 1.798 2.911 12.527 4.708 17.235 0.892 0.618 0.169 0.273
diff 0.838 0.072 0.146 0.152 0.910 0.298 1.208 0.002 
-
0.007
-
0.003 -0.002
ratio 1.081 1.056 1.088 1.055 1.078 1.068 1.075     
           
3
state
table 2 Status 
Quo    12.580 4.520 17.100    0.264
safety 10%    13.430 4.850 18.270    0.265
From Table 2, diff2 0.850 0.330 1.170    0.001
ratio     1.068 1.073 1.068     
             
    
factor 
=  -0.33        
             
summary table for equal YHL ICU intervention   
hh sh hs ss yhl ysl yol hh/yhl ss/ysl ss/yol ysl/yol
5
state
Status
Quo 10.331 1.286 1.652 2.758 11.617 4.410 16.027 0.889 0.625 0.172 0.275
icu
10% 10.825 1.528 1.817 3.913 12.353 5.729 18.082 0.876 0.683 0.216 0.317
diff 0.494 0.242 0.165 1.154 0.736 1.319 2.055 -0.013 0.057 0.044 0.042
ratio 1.048 1.189 1.100 1.418 1.063 1.299 1.128     
           
3
state
table 2 Status 
Quo    12.580 4.520 17.100    0.264
icu 10%    13.550 5.710 19.260    0.296
From Table 2, diff2 0.970 1.190 2.160    0.032
ratio     1.077 1.263 1.126     
             
    
factor 
=  -0.43        
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Appendix Table B 
Appendix Tables B 
New Summary--alpha needed to give same value as cure all- 
Retiree cohort 
Equivalent alpha    B = 
VYSL
/
VYHL
hp/dp tx safety icu 
cure all
(actual 
value) 
min
alpha
-0.2 0.109 0.152 0.266 0.381 0.58 0.109
0 0.11 0.155 0.226 0.272 0.54 0.11
0.1 0.111 0.156 0.208 0.233 0.51 0.111
0.2 0.112 0.157 0.191 0.202 0.49 0.112
0.3 0.114 0.159 0.176 0.176 0.46 0.114
0.4 0.115 0.161 0.161 0.154 0.44 0.115
0.5 0.116 0.163 0.148 0.136 0.42 0.116
0.6 0.118 0.165 0.135 0.12 0.39 0.118
0.7 0.12 0.168 0.123 0.105 0.37 0.105
0.8 0.123 0.171 0.112 0.093 0.35 0.093
0.9 0.126 0.175 0.101 0.082 0.32 0.082
1 0.129 0.179 0.091 0.072 0.3 0.072
        
New Summary--alpha needed to give same value as cure all- 
birth cohort
 Equivalent alpha    
b hp/dp tx safety icu
Value of 
cure all minimum
alpha
-0.2 0.0056 0.0071 0.02 0.0244 0.069 0.0056
0 0.0061 0.0078 0.0182 0.0201 0.067 0.0061
0.1 0.0064 0.0082 0.0174 0.0184 0.066 0.0064
0.2 0.0068 0.0087 0.0166 0.0169 0.065 0.0068
0.3 0.0072 0.0093 0.0159 0.0156 0.064 0.0072
0.4 0.0078 0.01 0.0153 0.0145 0.063 0.0078
0.5 0.0084 0.0108 0.0146 0.0135 0.063 0.0084
0.6 0.0091 0.0118 0.014 0.0126 0.062 0.0091
0.7 0.01 0.013 0.0135 0.0118 0.061 0.01
0.8 0.0111 0.0145 0.0129 0.0111 0.06 0.0111
0.9 0.0126 0.0165 0.0124 0.0104 0.059 0.0104
1 0.0146 0.0192 0.0119 0.0098 0.058 0.0098
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